The Huntington's disease research field is littered with failures but Bayer AG is hoping that a gene therapy developed at one of its subsidiaries will provide a significant advance in tackling the rare progressive neurodegenerative disorder.
Asklepios BioPharmaceutical, Inc. (AskBio), acquired by Bayer at the end of 2020 for $2bn upfront, has received clearance to...








